News Release Details

Former Pacific Biosciences executive brings deep expertise in single-molecule analysis to large-scale platform designed to comprehensively quantify the proteome

SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development. He and his team will work out of Nautilus’ research headquarters in San Carlos, California.

Dr. Voss brings more than 20 years of experience directing single-molecule biophysics and biochemistry, cell biology, and materials science research at leading biotechnology and life sciences companies. He was previously Vice President of Consumables Research and Development at Pacific Biosciences, where he led scientific efforts to productize the company’s long-read, single-molecule DNA sequencing instruments. Across 13 years, his roles in the development of the company’s Single Molecule, Real-Time (SMRT) Sequencing platform included driving the chemistry underlying SMRT, as well as contributing to instrument and software integration programs.

“With his deep expertise across research and development in single-molecule biochemistry, life sciences platforms, and systems integration, Karl has been instrumental in bringing a foundational long-read, single-molecule sequencing platform from prototype to product,” said Parag Mallick, Ph.D., co-founder and Chief Scientist of Nautilus. “We are excited to welcome him to our team as we seek to transform our understanding of human biology beyond the genome and drive the type of fundamental advancements in biomedical research that we believe our protein analysis platform can make possible.”

Prior to his work with Pacific Biosciences, Dr. Voss made substantial contributions at Cell Biosciences and Applied Biosystems. Dr. Voss received his B.S. in Biochemistry and Ph.D. in Analytical Chemistry from the University of Alberta.

“Nautilus is taking a truly revolutionary approach to unlocking the potential of proteomics – a relatively untapped but enormously valuable source of information about human biology,” said Dr. Voss. “I’m thrilled to join Nautilus’ stellar leadership team to further develop the first proteomics platform that will power a new era of precision therapies, tools, and applications.”

The appointment of Dr. Voss comes shortly after the debut of Nautilus as a publicly traded company and the appointments of Emma Lundberg to its Scientific Advisory Board and Matt Murphy as General Counsel. Nautilus completed a business combination with Arya Sciences Acquisition Corp III and received gross proceeds from the transaction totaling approximately $345 million to develop a protein analysis platform with the potential to quantify more than 95% of the proteome. Through innovations in computer science, engineering, and biochemistry, the Nautilus Proteomic Analysis Platform is designed to leverage a nanofabricated, large-scale, single-molecule protein array, multi-cycle imaging, and machine learning analysis to measure the proteome with extreme sensitivity and scale.

About Nautilus Biotechnology, Inc.
Based in Seattle, Washington, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio

Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as “may,” “will,” “could,” “can,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “poised,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential functionality and performance of Nautilus’ product platform, its potential impact on pharmaceutical development and drug discovery, and market opportunities available to Nautilus generally. These statements are based on numerous assumptions concerning the development of Nautilus’ products and target markets and involve substantial risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievement to be materially different from the information expressed or implied by these forward-looking statements. We cannot assure you that the forward-looking statements in this press release or the assumptions upon which they are based will prove to be accurate. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the Registration Statement on Form S-1 and related documents filed with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Disclosure Information
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD.

Media Contact
Thermal for Nautilus Biotechnology
Kaustuva Das
press@nautilus.bio

Investor Contact
investorrelations@nautilus.bio